Alzheimer DiseaseNCT07638449
Silkworm Pupa Powder Improves Alzheimer's Disease
A study testing Silkworm pupa powder in people with Alzheimer Disease and Sarcopenia, run by Zhejiang Provincial Tongde Hospital at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. Read more about this study
- Who is it for?
- Ages 50 to 90 years
- Conditions the study is for
- Alzheimer Disease, Sarcopenia, Asthenia
- What is being tested?
- Silkworm pupa powder
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.
- Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):
- Aβ positivity: Plasma Aβ42/40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).
- Tau positivity: Plasma p-tau217 ≥2.5 pg/mL (or CSF p-tau181/Aβ42 ratio ≥0.02).
- Age 50 to 90 years (inclusive), male or female, with at least a primary school education.
- Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.
Show all 11Show fewer
- Hachinski Ischemia Scale (HIS) total score ≤4.
- Geriatric Depression Scale-15 (GDS-15) total score ≤4.
- Neuroimaging evidence: Screening CT/MRI showing age-related brain changes or cerebral atrophy.
- Participant has a stable and reliable caregiver, as confirmed by the investigator.
- Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants must agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.
Who cannot join
- Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.
- Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.
- Abnormally low folate and/or vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.
- Comorbid psychiatric disorders.
- Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.
- Intolerance or allergy to the study medication (silkworm pupa powder).
Show all 17Show fewer
- Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.
- Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.
- Geriatric Depression Scale-15 (GDS-15) score >4 at screening.
- Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.
- Administration of any new chemical entity in an AD clinical study within 6 months prior to screening.
- Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures or safety.
- Participation in a clinical study involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening.
- Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapy and any BACE inhibitor therapy).
- Any inadequately controlled immune disorder, or immune disease requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.
- Inadequately controlled bleeding disorders (including platelet count <50,000 or INR >1.5 for participants not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have their anticoagulation status optimized and receive a stable dose within 4 weeks prior to screening. Participants receiving anticoagulant therapy must not participate in cerebrospinal fluid (CSF) assessments.
- Participation in another concurrent silkworm pupa powder intervention study conducted at the same study center.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Tongde Hospital of Zhejiang Province
Hangzhou, Zhejiang, 310012
Jiangtao Zhang, Phd, 8618969125501, 18969125501@163.com
About this study
Official title: A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients
The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:
- Does silkworm pupa powder improve cognitive function and daily living abilities?
- Does silkworm pupa powder improve nutritional status and frailty?
- What medical problems do participants have when taking silkworm pupa powder?
Read more
Researchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.
Participants will:
- Take silkworm pupa powder every day for 12 weeks
- Visit the clinic once every 4 weeks for checkups and tests
- Use an electronic punch-card system daily and report any symptoms
- Conditions
- Alzheimer Disease, Sarcopenia, Asthenia, Frailty
- Being tested
- Silkworm pupa powder
- Keywords
- Silkworm Pupa Powder, Nutritional Status, Frailty State, Cognitive Function, Dietary Supplement
- Medical subject headings
- Alzheimer Disease, Sarcopenia, Asthenia, Frailty
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Silkworm pupa powderDietary supplement
Silkworm pupa powder, 2 times a day, two packets (12*2 g) each time, take with warm water, before meals, for three months
| Study group | Role | What they receive |
|---|---|---|
| Group | Experimental | Silkworm pupa powder, 2 times a day, two packets (12*2 g) each time, take with warm water, before meals, for three months Receives: Dietary Supplement: Silkworm pupa powder |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
The ADAS-Cog is a tool designed to assess the severity of cognitive impairment in patients with Alzheimer's disease (AD). It consists of 12 items that evaluate multiple cognitive domains, including memory, orientation, language, praxis (practical ability), attention, and others. Through a series of standardized cognitive tasks, it measures the severity of AD-related cognitive symptoms and tracks changes in response to treatment. Higher total scores indicate more severe cognitive impairment.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm
Bilateral Hippocampal Volume
Bilateral hippocampal volume will be measured using 3.0T structural MRI T1-weighted imaging. Lower hippocampal volume indicates greater AD-related brain atrophy.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Entorhinal Cortex Volume
Entorhinal cortex volume will be measured using 3.0T structural MRI T1-weighted imaging. Lower volume indicates greater AD-related brain atrophy.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Temporoparietal Regional Volume
Temporoparietal regional volume will be measured using 3.0T structural MRI T1-weighted imaging. Lower volume indicates greater AD-related brain atrophy.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Cortical Thickness of AD-Related Brain Regions
Cortical thickness in AD-related brain regions, including the entorhinal cortex and temporoparietal cortex, will be measured using 3.0T structural MRI. Lower cortical thickness indicates greater cortical atrophy.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Fractional Anisotropy
Fractional anisotropy will be measured using diffusion tensor imaging to assess white matter microstructural integrity. Lower fractional anisotropy generally indicates reduced white matter integrity.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Mean Diffusivity
Mean diffusivity will be measured using diffusion tensor imaging to assess white matter microstructural changes. Higher mean diffusivity generally indicates greater microstructural disruption.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Radial Diffusivity
Radial diffusivity will be measured using diffusion tensor imaging to assess white matter microstructural changes. Higher radial diffusivity generally indicates greater white matter microstructural abnormality.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Default Mode Network Functional Connectivity
Functional connectivity of the default mode network will be assessed using resting-state functional MRI to evaluate AD-related brain network function.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Salience Network Functional Connectivity
Functional connectivity of the salience network will be assessed using resting-state functional MRI to evaluate AD-related brain network function.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Amplitude of Low-Frequency Fluctuations
Amplitude of low-frequency fluctuations will be measured using resting-state functional MRI to assess local spontaneous neuronal activity.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Regional Homogeneity
Regional homogeneity will be measured using resting-state functional MRI to assess local synchronization of neuronal activity.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Blood Neurofilament Light Chain Concentration
Neurofilament light chain concentration in blood will be measured as a biomarker of neuronal injury and neurodegeneration. Higher concentrations generally indicate greater neuronal injury.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Aβ42 Concentration in Blood or Cerebrospinal Fluid
Aβ42 concentration in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Aβ40 Concentration in Blood or Cerebrospinal Fluid
Aβ40 concentration in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Aβ42/Aβ40 Ratio in Blood or Cerebrospinal Fluid
The Aβ42/Aβ40 ratio in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Phosphorylated Tau 181 Concentration in Blood or Cerebrospinal Fluid
Phosphorylated tau 181 concentration in blood or cerebrospinal fluid will be measured as a biomarker of tau pathology in Alzheimer's disease.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Phosphorylated Tau 217 Concentration in Blood or Cerebrospinal Fluid
Phosphorylated tau 217 concentration in blood or cerebrospinal fluid will be measured as a biomarker of tau pathology in Alzheimer's disease.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Secondary outcomes (2)
CIBIC-plus Score
The Clinician's Interview-Based Impression of Change Plus Caregiver Input is a semi-structured interview tool used to assess global clinical change in patients with dementia after treatment. The score ranges from 1 to 7, with 1 indicating very much improved, 4 indicating no change, and 7 indicating very much worsened.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
MMSE Total Score
Mini-Mental State Examination (MMSE): A validated 30-point cognitive screening tool evaluating domains including orientation, memory, attention, language, and visuospatial abilities. Rationale: The dual assessment leverages: CIBIC-plus for holistic, clinician-judged disease progression (anchored to baseline severity). MMSE for quantifiable tracking of specific cognitive deficits.
Measured: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2026
- Study start1 Jun 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhejiang Provincial Tongde Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jiangtao Zhang, Zhejiang Provincial Tongde Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07638449
- Sponsor's protocol ID
- 2026-063(L)-F1
- Status last verified
- Jun 2026
- First submitted
- 29 May 2026
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients
- ClinicalTrials.gov ID
- NCT07638449
- Acronym / sponsor ID
- 2026-063(L)-F1
- Conditions
- Alzheimer Disease, Sarcopenia, Asthenia, Frailty
- Keywords
- Silkworm Pupa Powder, Nutritional Status, Frailty State, Cognitive Function, Dietary Supplement
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Zhejiang Provincial Tongde HospitalUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 10 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:
- Does silkworm pupa powder improve cognitive function and daily living abilities?
- Does silkworm pupa powder improve nutritional status and frailty?
- What medical problems do participants have when taking silkworm pupa powder?
Researchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.
Participants will:
- Take silkworm pupa powder every day for 12 weeks
- Visit the clinic once every 4 weeks for checkups and tests
- Use an electronic punch-card system daily and report any symptoms
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group | Experimental | Dietary Supplement: Silkworm pupa powderSilkworm pupa powder, 2 times a day, two packets (12*2 g) each time, take with warm water, before meals, for three months |
Who may qualify
- Ages
- 50 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.
- Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):
- Aβ positivity: Plasma Aβ42/40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).
- Tau positivity: Plasma p-tau217 ≥2.5 pg/mL (or CSF p-tau181/Aβ42 ratio ≥0.02).
- Age 50 to 90 years (inclusive), male or female, with at least a primary school education.
Key exclusion criteria (17 listed)
- Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.
- Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.
- Abnormally low folate and/or vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.
- Comorbid psychiatric disorders.
- Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Silkworm pupa powderSilkworm pupa powder, 2 times a day, two packets (12*2 g) each time, take with warm water, before meals, for three months | Dietary supplement | Group |
Primary outcome
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm
The ADAS-Cog is a tool designed to assess the severity of cognitive impairment in patients with Alzheimer's disease (AD). It consists of 12 items that evaluate multiple cognitive domains, including memory, orientation, language, praxis (practical ability), attention, and others. Through a series of standardized cognitive tasks, it measures the severity of AD-related cognitive symptoms and tracks changes in response to treatment. Higher total scores indicate more severe cognitive impairment.
Bilateral Hippocampal Volume
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Bilateral hippocampal volume will be measured using 3.0T structural MRI T1-weighted imaging. Lower hippocampal volume indicates greater AD-related brain atrophy.
Entorhinal Cortex Volume
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Entorhinal cortex volume will be measured using 3.0T structural MRI T1-weighted imaging. Lower volume indicates greater AD-related brain atrophy.
Temporoparietal Regional Volume
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Temporoparietal regional volume will be measured using 3.0T structural MRI T1-weighted imaging. Lower volume indicates greater AD-related brain atrophy.
Cortical Thickness of AD-Related Brain Regions
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Cortical thickness in AD-related brain regions, including the entorhinal cortex and temporoparietal cortex, will be measured using 3.0T structural MRI. Lower cortical thickness indicates greater cortical atrophy.
Fractional Anisotropy
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Fractional anisotropy will be measured using diffusion tensor imaging to assess white matter microstructural integrity. Lower fractional anisotropy generally indicates reduced white matter integrity.
Mean Diffusivity
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Mean diffusivity will be measured using diffusion tensor imaging to assess white matter microstructural changes. Higher mean diffusivity generally indicates greater microstructural disruption.
Radial Diffusivity
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Radial diffusivity will be measured using diffusion tensor imaging to assess white matter microstructural changes. Higher radial diffusivity generally indicates greater white matter microstructural abnormality.
Default Mode Network Functional Connectivity
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Functional connectivity of the default mode network will be assessed using resting-state functional MRI to evaluate AD-related brain network function.
Salience Network Functional Connectivity
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Functional connectivity of the salience network will be assessed using resting-state functional MRI to evaluate AD-related brain network function.
Amplitude of Low-Frequency Fluctuations
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Amplitude of low-frequency fluctuations will be measured using resting-state functional MRI to assess local spontaneous neuronal activity.
Regional Homogeneity
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Regional homogeneity will be measured using resting-state functional MRI to assess local synchronization of neuronal activity.
Blood Neurofilament Light Chain Concentration
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Neurofilament light chain concentration in blood will be measured as a biomarker of neuronal injury and neurodegeneration. Higher concentrations generally indicate greater neuronal injury.
Aβ42 Concentration in Blood or Cerebrospinal Fluid
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Aβ42 concentration in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
Aβ40 Concentration in Blood or Cerebrospinal Fluid
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Aβ40 concentration in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
Aβ42/Aβ40 Ratio in Blood or Cerebrospinal Fluid
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
The Aβ42/Aβ40 ratio in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
Phosphorylated Tau 181 Concentration in Blood or Cerebrospinal Fluid
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Phosphorylated tau 181 concentration in blood or cerebrospinal fluid will be measured as a biomarker of tau pathology in Alzheimer's disease.
Phosphorylated Tau 217 Concentration in Blood or Cerebrospinal Fluid
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Phosphorylated tau 217 concentration in blood or cerebrospinal fluid will be measured as a biomarker of tau pathology in Alzheimer's disease.
2 secondary outcomes
CIBIC-plus Score
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
MMSE Total Score
Time frame: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Silkworm pupa powder in people with Alzheimer Disease and Sarcopenia, run by Zhejiang Provincial Tongde Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiangtao Zhang (+8618969125501, 18969125501@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) (time frame: The 0th、 4th 、8th and 12th week after taking Silkworm). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.